

19. The protein of claim 18, wherein the Tet repressor is a Tn10-derived Tet repressor.

20. The protein of claim 18, wherein the second polypeptide comprises a transcription activation domain of herpes simplex virion protein 16.

21. The protein of claim 19, wherein the second polypeptide comprises the C-terminal 130 amino acids of herpes simplex virion protein 16.

22. The protein of claim 18, wherein the second polypeptide comprises a transcription activation domain selected from the group consisting of an acidic transcription activation domain, a proline-rich transcription activation domain, a serine/threonine-rich transcription activation domain and a glutamine-rich transcription activation domain.--

REMARKS

Claim 1 was originally filed in the application. New claims 18-22 have been added. Accordingly, claims 1 and 18-22 are pending.

The title has been amended to more accurately reflect the subject being claimed in the application. The specification also has been amended to correct a number of minor informalities. New claims 18-22 are directed to transcriptional activator fusion proteins. Support for these claims can be found in the specification at, for example, pages 24, line 22 through page 26, line 1 and in Example 1 (pages 41-49).

No new matter has been added by way of the amendments to the specification or the new claims. Applicants respectfully request that these amendments be entered.

SUMMARY

All pending claims are believed to be in condition for allowance. If a telephone conversation with Applicants' Agent would expedite the prosecution of the above-


Applicants: H. Buja and M. Gossen

-7-

Filing Date: September 29, 1998

identified application, the examiner is urged to call Applicants' Agent at (617) 227-7400.

Respectfully submitted,



Catherine J. Kara, Ph.D.  
Registration No. 41,106  
Agent for Applicants

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109  
Tel. (617) 227-7400  
Dated: September 29, 1998